Frontiers | Complement System Part I – Molecular Mechanisms of Activation and Regulation | Immunology

AI, BIO, DRUG-STENTS, VR, PSYCHIATRIX, PILOT PROJECTS
Frontiers | Complement System Part I – Molecular Mechanisms of Activation and Regulation
Exagen, Inc. | UT Southwestern
Exagen, Inc. | UT Southwestern
cell-bound complement activation products -lupus - Google Search
Tal Varsano on Twitter / X
The mechanism of activation of the alternative pathway of complement by cell-bound C4b
Complement Activation - an overview | ScienceDirect Topics
Frontiers | The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy | Immunology
Frontiers | The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy
SLE and Serum Complement: Causative, Concomitant or Coincidental?
Human T cell derived, cell-bound complement iC3b is integrally involved in T cell activation - PubMed
- YouTube
WIPO - Search International and National Patent Collections
cell-bound complement activation products -lupus - Google Search
Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity - J S Hui-Yuen, Y Gartshteyn, M Ma, T O’Malley, J Conklin, A H Eichenfield, L F Imundo, T Dervieux, A D Askanase, 2018
cell-bound complement activation products - Google Search
Activation of the classical pathway complement system has long been implicated in stimulating immune complex mediated tissue destruction in systemic lupus erythematosus (SLE). C3 and C4 complement levels are utilized as part of SLE diagnosis and monitoring criteria. Recently, cell bound complement activation products (CBCAPs) have shown increased sensitivity in diagnosing and monitoring lupus activity, compared to traditional markers. CBCAPs are increasingly utilized in rheumatology practice as additional serological markers in evaluating SLE patients. We report a case of a patient diagnosed with SLE that had chronically low C3 and C4, along with negative CBCAPs. We surmise that the patient has an inherited complement deficiency as the etiology of her SLE and that CBCAPs could be used to predict such deficiency.
https://www.google.com/url?cd=&esrc=s&q=&rct=j&sa=t&source=web&url=https%3A%2F%2Fwww.jimmunol.org%2Fcontent%2F202%2F1_Supplement%2F182.8&usg=AOvVaw0fMs6gczO8GZE8KuuaZHTq&ved=2ahUKEwjc8LnNxOfxAhWCHM0KHaLJDh4QFnoECBIQAA
ell-bound complement activation products - Google Search
quiescent - Google Search
serologically active clinically quiescent (SACQ) - Google Search
T-bet + CD11c + B cells are critical for antichromatin immunoglobulin G production in the development of lupus | Arthritis Research & Therapy | Full Text
T-bet+CD11c+ B cells are critical for antichromatin immunoglobulin G production in the development of lupus - Arthritis Research & Therapy
Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen.
Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus
054D9F1A-BD92-1E82-88C3B4ADDE8398BB.pdf
April 13, 2020 COVID Task Force Meeting
April 13, 2020 COVID Task Force Meeting
Gibson Dunn | U.S. Cybersecurity and Data Privacy Outlook and Review: 2017